Table 2.

Independent review committee-assessed response (full analysis population).

Response category	Lyophilised belantamab mafodotin 3.4 mg/kg (N = 25)
Best response
Very good partial response (VGPR)	6 (24)
Partial response (PR)	7 (28)
Minimal response (MR)	1 (4)
Stable disease	4 (16)
Progressive disease	6 (24)
Not evaluable	1 (4)
Overall response rate (ORR)a	13 (52) (95% CI: 31.3–72.2)
Clinical benefit rate (CBR)b	14 (56) (95% CI: 34.9–75.6)

Data are n (%) unless otherwise specified. No patients had stringent complete response (sCR) or complete response (CR).

^aORR included sCR+CR + VGPR + PR.

^bCBR included sCR+CR + VGPR + PR + MR.